Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.

Autor:	Bhanushali A; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Atre S; Dr. D.Y. Patil Medical College Hospital and Research Centre, Pune, India., Nair P; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Thandaseery GA; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Shah S; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Kuruwa S; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Zade A; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India., Nikam C; Thyrocare Technologies Ltd., Navi Mumbai, India., Gomare M; BrihanMumbai Municipal Corporation, Mumbai, India., Chatterjee A; HaystackAnalytics Pvt. Ltd., IIT Bombay, Mumbai, India.
Jazyk:	angličtina
Zdroj:	Microbiology spectrum [Microbiol Spectr] 2024 May 02; Vol. 12 (5), pp. e0277023. Date of Electronic Publication: 2024 Apr 10.
DOI:	10.1128/spectrum.02770-23
Abstrakt:	Treatment decisions for tuberculosis (TB) in the absence of full drug-susceptibility data can result in amplifying resistance and may compromise treatment outcomes. Genomics of Mycobacterium tuberculosis ( M.tb ) from clinical samples enables detection of drug resistance to multiple drugs. We performed whole-genome sequencing (WGS) for 600 clinical samples from patients with tuberculosis to identify the drug-resistance profile and mutation spectrum. We documented the reasons reported by clinicians for referral. WGS identified a high proportion (51%) of pre-extensively drug-resistant (pre-XDR) cases followed by multidrug-resistant tuberculosis (MDR-TB) (15.5%). This correlates with the primary reason for referral, as non-response to the first-line treatment (67%) and treatment failure or rifampicin resistance (14%). Multivariate analysis indicated that all young age groups ( P < 0.05), male gender ( P < 0.05), and Beijing strain ( P < 0.01) were significant independent predictors of MDR-TB or MDR-TB+ [pre-extensively drug-resistant tuberculosis (XDR-TB) and XDR-TB]. Ser315Thr (72.5%) in the inhA gene and Ser450Leu in the rpoB gene (65.5%) were the most prevalent mutations, as were resistance-conferring mutations to pyrazinamide (41%) and streptomycin (61.33%). Mutations outside the rifampicin resistance-determining region (RRDR), Ile491Phe and Val170Phe, were seen in 1.3% of cases; disputed mutations in rpoB (Asp435Tyr, His445Asn, His445Leu, and Leu430Pro) were seen in 6% of cases, and mutations to newer drugs such as bedaquiline and linezolid in 1.0% and 7.5% of cases, respectively. This study on clinical samples highlights that there is a high proportion of pre-XDR cases and emerging resistance to newer drugs; ongoing transmission of these strains can cause serious threat to public health; and whole-genome sequencing can effectively identify and support precision medicine for TB. Importance: The current study is based on real-world data on the TB drug-resistance profile by whole-genome sequencing of 600 clinical samples from patients with TB in India. This study indicates the clinicians' reasons for sending samples for WGS, which is for difficult-to-treat cases and/or relapse and treatment failure. The study reports a significant proportion of cases with pre-XDR-TB strains that warrant policy makers' attention. It reflects the current iterative nature of the diagnostic tests under programmatic conditions that leads to delays in appropriate diagnosis and empirical treatment. India had an estimated burden of 2.95 million TB cases in 2020 and 135,000 multidrug-resistant cases. However, WGS profiles of M.tb from India remains disproportionately poorly represented. This study adds a significant body of data on the mutation profiles seen in M.tb isolated from patients with TB in India, mutations outside the RRDR, disputed mutations, and resistance-conferring mutations to newer drugs such as bedaquiline and linezolid. Competing Interests: A.C., A.Z., A.B., P.N., G.A.T., S.S., and S.K. are employees of HaystackAnalytics Pvt Ltd., which provides commercial genomics services. Other authors declare no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu